Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simpinicline
- Development stage
- Phase 2
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Simpinicline is a small molecule drug that acts as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, with strong activity at the α4β2, α3β4, α3α5β4, and α4α6β2 receptors and weaker activity at the α7 receptor. It has been investigated primarily as an aqueous nasal spray for the treatment of dry eye disease, where it stimulates nAChRs in the nasal cavity to increase natural tear production via activation of the nasolacrimal reflex. Simpinicline has also been studied for irritable bowel syndrome and gastroparesis in clinical trials. The drug was developed by Oyster Point Pharmaceuticals[1][3][5][6].
- Brand names
- OC-02OC02OC 02
- Other names
- Simpinicline citrate
02
Targets
CHRNA7 (α7 nicotinic receptor)α4α6β2 nAChR (α4α6β2 nicotinic receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)α3α5β4 nAChR (α3α5β4 nicotinic receptor)
Beyond the preview
Go deeper on simpinicline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simpinicline.